IDWeek is taking place in person for the first time in 3 years.
Infectious disease professionals from around the world are set to gather in Washington, D.C. this week for the first live IDWeek meeting in 3 years, held from October 19 to October 23 at the Walter E. Washington Convention Center.
Over the course of the conference, IDWeek partners—including the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Disease Society (PIDS), and the Society of Infectious Disease Pharmacists (SIDP)—will offer more than 140 scientific sessions, hundreds of research abstracts, and hours continuing education credits for both virtual and in-person attendees.
For pharmacists, SIDP will hold their Annual Business Meeting and Reception on October 18, featuring a keynote address by Ilisa Bernstein, PharmD, JD, FAPhA, interim CEO and executive vice president of the American Pharmacists Association (APhA), focused on advocating for infectious disease pharmacy.
This year, IDWeek is offering all virtual attendees complimentary access to sessions in the COVID-19 track, thanks to funding from the CDC and the IDSA Foundation. These sessions will be available for livestream from October 19 to 23, and on-demand through March 31.
Drug Topics® will be live in Washington, D.C. all week, providing the latest insights and education around infectious diseases. Be sure to check back daily and subscribe to our eNewsletters for the latest updates from IDWeek 2022.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.